ONCOTAG Diagnostics Co., Ltd of Suwon-si, Gyeonggi-do at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair

ONCOTAG Diagnostics Co., Ltd

B-9 AICT, Gwanggyo-ro 145, Yeongtong-gu, 16229 Suwon-si, Gyeonggi-do
Korea, Republic

Hall map

MEDICA 2019 hall map (Hall 1): stand D70

Fairground map

MEDICA 2019 fairground map: Hall 1

Contact

JEONGWOO SHIN

Phone
+82 31 888 9280
+82 10 8842 9724

Email
jwshin@oncotag.com

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

ONCOTAG-M antibody, TAG201

Murine monoclonal antibody used for qualitative identification of normal cells and malignant cells of bile duct sections (paraffin and frozen) and cytocentrifuge preparations.
Oncotag-M Antibody, TAG201 is an antibody to recognize human methionyl-tRNA synthease (MRS) protein that is highly expressed in bile duct carcinomas. Oncotag-M Antibody, TAG201 is useful for distinguishing malignant biliary tumors from normal bile duct cells.

More Less

Product category: Diagnostic tests for cancer

ONCOTAG-M Cytology kit, TAG101

Current diagnostic accuracy (eg. PAP stain) of bile duct and pancreatic cancer was 40~60% and 5 years survival rate  was less than 10%. Also, 82.4% (pancreas) and 81.3%(bile duct) of cancer patients were suffered by cancer pain.
Diagnostic accuracy for Cholangiocarcinoma of ONCOTAC-M Cytology kit, TAG101 is 97.9% specificity and 96.0% sensitivity. 
Furthermore, it can differentiate cancer from atypical cell and benign biliary strictures accurately.

 

More Less

About us

Company details

Oncotag Diagonstics contribute to healthy human life by innovating tissue diagnostic solutions and providing high-quality diagnostic product based on intellectual properties.
Without competitive company with our product and superior diagnostic sensitivity comparing with current gold standard staining method, we expect our products will be global standard method in pancreatobilliary cancer cytology test area in near future.
Furthermore new application of oncotag-M biomarker and detection antibody on cancer diagnosis and therapeutic area we are preparing now will add up our commercial value in near future.

More Less